FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.
What happened
FDA inspected the clinical site from September 19 to October 26, 2022, as part of its Bioresearch Monitoring Program. It found that Dr. Epstein, as sponsor-investigator, started and ran Protocol PXL-330, a study of riboflavin solutions with UVA light, in 32 subjects without submitting or having an IND in effect. It also found inadequate records of receipt, shipment, and other disposition of the investigational drugs.
What FDA found
Dr. Epstein started and ran a clinical trial of investigational drugs in 32 subjects without submitting an IND or having one in effect.
21 CFR 312.20(a), 312.20(b), and 312.40(a)Dr. Epstein did not keep adequate records showing receipt, shipment, or other disposition of the investigational riboflavin solutions.
21 CFR 312.57(a)
What FDA wants
FDA asks Dr. Epstein to notify the office in writing within 15 business days of receipt of the letter about actions taken to prevent similar violations. It says failure to adequately address the matter may lead to regulatory action.
Who should pay attention
- sponsor-investigators running investigator-initiated trials
- clinical research sites and IRBs
- companies relying on investigator-run trial data
This is a summary. Read the original letter on fda.gov.